Patent classifications
C07C311/37
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
##STR00001##
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
Inhibitors of HBV replication of Formula (I) ##STR00001##
including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
Inhibitors of HBV replication of Formula (I) ##STR00001##
including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Polymorphic forms of belinostat and processes for preparation thereof
The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
Polymorphic forms of belinostat and processes for preparation thereof
The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
Inhibitors of HBV replication of Formula (I)
##STR00001##
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
Inhibitors of HBV replication of Formula (I)
##STR00001##
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
SELECTIVE SHIP INHIBITORS FOR TREATING DISEASE
The present disclosure provides compositions that inhibit the SH2-containing inositol 5-phosphatase (SHIP), as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition in a subject.
SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
Inhibitors of HBV replication of Formula (I)
##STR00001##
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
Inhibitors of HBV replication of Formula (I)
##STR00001##
including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R.sub.1, R.sub.2 and R.sub.4 have the meaning as defined herein.
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.